Indacaterol: in chronic obstructive pulmonary disease.

Abstract

Indacaterol is a long-acting β₂-adrenoceptor agonist that is available in the EU for the maintenance treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD). Indacaterol has a 24-hour bronchodilatory effect, which allows for once-daily administration. The onset of bronchodilation after inhalation of indacaterol is fast, with significant improvements versus placebo seen 5 minutes after inhalation. In four large (n > 400), randomized, double-blind, placebo-controlled, multicentre phase III trials, patients with COPD who received indacaterol 150 or 300 μg once daily had a significantly higher mean trough forced expiratory volume in 1 second (FEV₁) than placebo recipients after 12 weeks. Trough FEV₁ differences between indacaterol and placebo recipients were 130-180 mL and exceeded the clinically relevant threshold of 120 mL in all trials. Furthermore, indacaterol recipients had significantly higher mean trough FEV₁ values after 12 weeks than patients who received formoterol, salmeterol or open-label tiotropium. COPD exacerbations and symptoms, and health-related quality of life were also significantly improved for indacaterol versus placebo recipients in some studies. Indacaterol was generally well tolerated by adults with moderate to severe COPD.

• Authors: Marit D Moen
• Journal: Drugs (Drugs) Vol. 70 Issue 17 Pg. 2269-80 (Dec 03 2010) ISSN: 1179-1950 [Electronic] New Zealand
• PMID: 21080743 (Publication Type: Journal Article, Review)

Chemical References

• Adrenergic beta-2 Receptor Agonists
• Indans
• Quinolones
• Vasodilator Agents
• indacaterol

Topics

• Adrenergic beta-2 Receptor Agonists (therapeutic use)
• Animals
• Clinical Trials, Phase III as Topic
• Forced Expiratory Volume (drug effects)
• Humans
• Indans (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
• Pulmonary Disease, Chronic Obstructive (drug therapy)
• Quinolones (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
• Vasodilator Agents (therapeutic use)